Prostate Cancer
Prostate cancer is the second most common cancer in men, characterized by the uncontrolled growth of cells in the prostate gland. It typically grows slowly and is often detected through elevated prostate-specific antigen (PSA) levels in blood tests, with the risk factors including a Western diet rich in dairy products.
Health Outcomes
- Activated Wnt/Beta-Catenin Signaling
- Activated p53/BAX-Mediated DNA Damage Response
- Additive Antitumorigenic Effect
- Altered Spermidine Levels
- Cancer Treatment Support
- Delayed Tumor Onset
- Enhanced Anticancer Capacity
- Enhanced Antitumor Immune Response
- Enhanced Antitumor Immunity
- Enhanced CD8+ T Cell Infiltration
- Enhanced Cell Adhesion
- Enhanced Cell Adhesion Capacity
- Enhanced Cell Viability
- Enhanced Cytolytic Response of CD8+ T Cells
- Enhanced DNA Repair
- Enhanced Glycolysis Pathway Activation
- Enhanced Natural Killer Cell Activity
- Enhanced Natural Killer Cell Tumor Killing Activity
- Enhanced Pro-Apoptotic MAPK Signaling
- Enhanced Protein Kinase C Activity
- Enhanced Tumor-Targeted Drug Delivery
- Estrogen Receptor-Mediated Effects
- Extended Survival Periods
- Genitourinary Adverse Events
- Genome Sequencing / Genome Characterization
- Identification of FDA Approved Drug Target Regulators
- Improved Antitumor Response
- Improved Cell Viability
- Improved Chemotherapy Efficacy
- Improved Dysuria
- Improved Effectiveness in Cancer Treatment
- Improved Efficacy Rate
- Improved Histopathological Indicators
- Improved Karnofsky Performance Status
- Improved NK-Cell Cytotoxicity
- Improved Natural Killer Cell Activation
- Improved Natural Killer Cell Activity
- Improved Natural Killer Cell Tumoricidal Activity
- Improved Objective Response Rate
- Improved Oncolytic Virotherapy Efficacy
- Improved Overall Survival
- Improved Prognosis Post-Recovery
- Improved Progression-free Survival
- Improved Prostate Health
- Improved Resistance to Sodium Selenite
- Improved Response to Immune Checkpoint Inhibitor Therapy
- Improved Serum Acid Phosphatase Activity
- Improved Survival
- Improved Survival Capacity
- Improved Survival Rate
- Improved Therapeutic Potential
- Improved Treatment Response Rate
- Improved Tumor Response
- Improved Urinary Flow Measure
- Improved Urogenital Tract Symptoms
- Inactivated Other Receptor Tyrosine Kinase Activity
- Increased Acid Phosphatase Activity
- Increased Anti-Tumor Activity
- Increased Antiangiogenic Activity
- Increased Anticancer Activity
- Increased Anticancer Treatment Adherence
- Increased Cell Death
- Increased Cell Division
- Increased Cellular Adhesion
- Increased Choline Level
- Increased Chromosomal Instability
- Increased Cure Rate after Conventional Treatment
- Increased Ejaculation Volume
- Increased Epithelial Proliferation
- Increased Insulin-like Growth Factor-1 Level
- Increased Intratumoral Accumulation
- Increased Intratumoral CD8+ T-cell Expansion
- Increased Invasive Interventions Requirement
- Increased Lesion Detection Rate
- Increased Mitogenic Activity
- Increased NK Cell Activity
- Increased Plasma Daidzein Levels
- Increased Polyamine Levels
- Increased Polyamine Production
- Increased Pro-apoptotic Factor Levels
- Increased Proximal Tibial Cortical Volumetric Bone Mineral Density
- Increased Reduced Glutathione Level
- Increased Relative Survival Percentage
- Increased Selenium Absorption
- Increased Survival Rate
- Increased Survival Time
- Increased Telomere Length
- Increased Tissue Invasion
- Increased VEGF Level
- Increased mTORC1 Activation
- Induction of Specific CD8+ T Cells
- Influenced Cell Differentiation
- Inhibited Activation of Apoptotic Biomarkers
- Inhibited EGF Receptor Signaling
- Inhibited Epithelial-Mesenchymal Transition
- Inhibited PI3K/AKT Pathway
- Maintained Natural Killer Cell Activity
- Maintained Polyamine Levels
- No Improvement in Objective Cancer Treatment Response
- No Mutagenicity
- No Serious Treatment-Related Adverse Events
- No Significant Change in Androgen Levels
- Occurrence of Unrelated Haematuria
- Overall Treatment Success
- Reduced Apoptosis Due to Carcinogens
- Reduced Cancer Activity
- Reduced Cancer Progression
- Reduced Cancer Risk
- Reduced Cancer-Related Inflammation
- Reduced Cancer-Specific Mortality
- Reduced Carcinogenesis
- Reduced Caspase-3 Activity
- Reduced Cause-Specific Mortality
- Reduced Cell Adhesion
- Reduced Cell Apoptosis
- Reduced Chemotherapy Side Effects
- Reduced DNA Damage
- Reduced Epithelial Cell Apoptosis
- Reduced Epithelial-Mesenchymal Transition
- Reduced Expression of Beta-Catenin
- Reduced Expression of STAT3-Dependent Tumor-Associated Genes
- Reduced Genotoxicity
- Reduced Hydronephrosis
- Reduced IkappaB Alpha Degradation
- Reduced Plasma Equol Concentration
- Reduced Prostate Inflammation
- Reduced Pulmonary Metastasis
- Reduced Radiation-Associated Diarrhea
- Reduced Recurrence Risk
- Reduced Risk of Cancer
- Reduced Survival Rate
- Reduced Tumor Downstaging
- Reduced Tumor Formation
- Reduced Tumor Grade
- Reduced Tumor Growth
- Reduced Tumor Growth Rate
- Reduced Tumor Incidence
- Reduced Tumor Multiplicity
- Reduced Tumor Risk
- Reduced Tumor Stage
- Reduced Tumor Volume
- Reduced Urinary Urgency
- Regulated miR-130a-5p Levels
- Shifted Tumor-Associated Macrophages Toward Pro-Inflammatory M1 Polarization
- Stable Androgen Levels
- Suppressed Tumor Growth
- Suppressed Wnt/β-catenin Signaling
- Targeted Tumor Reduction